BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 26417069)

  • 1. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
    Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy.
    Mucha O; Podkalicka P; Kaziród K; Samborowska E; Dulak J; Łoboda A
    Skelet Muscle; 2021 Sep; 11(1):21. PubMed ID: 34479633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin provides long-term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy.
    Kim MJ; Bible KL; Regnier M; Adams ME; Froehner SC; Whitehead NP
    Physiol Rep; 2019 Mar; 7(6):e14018. PubMed ID: 30912308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced autophagy as a potential mechanism for the improved physiological function by simvastatin in muscular dystrophy.
    Whitehead NP
    Autophagy; 2016; 12(4):705-6. PubMed ID: 26890413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
    González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
    J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
    Hibaoui Y; Reutenauer-Patte J; Patthey-Vuadens O; Ruegg UT; Dorchies OM
    J Pineal Res; 2011 Sep; 51(2):163-71. PubMed ID: 21486366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
    Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
    Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.
    Xu D; Zhao L; Jiang J; Li S; Sun Z; Huang X; Li C; Wang T; Sun L; Li X; Jiang Z; Zhang L
    J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1306-1320. PubMed ID: 32869445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
    Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
    PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
    Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
    Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse.
    Farini A; Meregalli M; Belicchi M; Battistelli M; Parolini D; D'Antona G; Gavina M; Ottoboni L; Constantin G; Bottinelli R; Torrente Y
    J Pathol; 2007 Oct; 213(2):229-38. PubMed ID: 17668421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice.
    Rinaldi F; Zhang Y; Mondragon-Gonzalez R; Harvey J; Perlingeiro RCR
    Skelet Muscle; 2016; 6():21. PubMed ID: 27303621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.